Tandem Meetings 2022

Relapse Risk Lower With Double CBT Than With Matched Sibling or Unrelated Transplant

There was no significant difference in transplant-related mortality or overall survival.

Omidubicel May Provide Long-Term Benefits With Allogeneic Transplantation for Hematologic Malignancies

Researchers sought to determine whether there were long-term benefits for patients with hematologic malignancies treated with allo-HSCT and omidubicel.

Treosulfan Exposure and Transplantation Outcomes With Thalassemia Major

Researchers sought to determine whether there is a link between outcomes of hematopoietic transplantation and treosulfan exposure in high-risk thalassemia major.

Defibrotide Useful in Treating Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome

Researchers sought to determine whether defibrotide would be a useful treatment in patients with veno-occlusive disease/sinusoidal obstruction syndrome

Results Support Allo-HSCT After CAR-T Failure in Large B-Cell Lymphoma

The 1-year progression-free survival rate was 45%, and the 1-year overall survival rate was 59%.

Real-World Data Confirm Lack of Standard Care for Triple-Exposed Multiple Myeloma

After triple-class exposure, patients received more than 50 unique treatment regimens.

Allo-HSCT May Be Effective for Patients With Hepatosplenic T-Cell Lymphoma

Researchers sought to determine whether allo-HSCT would be helpful in treating patients with hepatosplenic T-cell lymphoma.

Adding Eprenetapopt to Maintenance Azacitidine Promising After HCT in MDS/AML

Researchers sought to determine whether adding eprenetapopt to maintenance azacitidine after HCT would be effective in patients with AML or MDS.

Beti-Cel Shows Promise in Patients With Transfusion-Dependent Beta-Thalassemia

Researchers sought to determine whether betibeglogene autotemcel would be safe and effective in patients with transfusion-dependent beta-thalassemia.

High-Dose Granulocyte Colony Stimulating Factor Mobilization Effective in Donors With Sickle Cell Trait

Researchers sought to determine whether high-dose granulocyte colony stimulating factor mobilization would be safe in adult donors with sickle cell disease trait undergoing PBSC collection for stem cell transplantation.

Costs of Care and Complication Rates Among Patients With Hematologic Malignancies Undergoing Allo-HCT

Researchers sought to determine the costs of care and health resource use of patients with hematologic malignancies undergoing allo-HCT.